John A Ligon, R Taylor Sundby, Mary F Wedekind, Fernanda I Arnaldez, Jaydira Del Rivero, Lori Wiener, Ramaprasad Srinivasan, Melissa Spencer, Amanda Carbonell, Haiyan Lei, John Shern, Seth M Steinberg, William D Figg, Cody J Peer, Sara Zimmerman, Josquin Moraly, Xia Xu, Stephen Fox, King Chan, Michael I Barbato, Thorkell Andresson, Naomi Taylor, Karel Pacak, J Keith Killian, Eva Dombi, W Marston Linehan, Markku Miettinen, Richard Piekarz, Lee J Helman, Paul Meltzer, Brigitte Widemann, John Glod
PURPOSE: Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT or platelet-derived growth factor receptor alpha mutations are often resistant to cytotoxic chemotherapy, radiotherapy, and many targeted therapies. We evaluated guadecitabine, a dinucleotide containing the DNA methyltransferase inhibitor decitabine, in these patient populations...
January 17, 2023: Clinical Cancer Research